Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children

11 Feb 2022

Abstract excerpt

Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare occurrence of disease and outbreaks associated with the genetic instability of the Sabin vaccine strains. Children aged 1 to 5 years were enrolled in two related clinical studies to assess safety, immunogenicity, shedding rates and properties of the shed virus following vaccination with nOPV2 (two candidates) versus traditional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to Viral Infections and Immunology Research
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35149714
DOI: 10.1038/s41541-022-00437-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in childrenPMID 35149714Read ↗

Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine virusesSemantic proximity Read ↗

Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsSemantic proximity Read ↗

Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3Semantic proximity Read ↗

Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to VirulenceSemantic proximity Read ↗

Developing genetically stable live-attenuated vaccine candidates against type 1 and 3 poliovirusSemantic proximity Read ↗

From Vaccine to Pathogen: Modeling Sabin 2 Vaccine Virus Reversion and Evolutionary EpidemiologySemantic proximity Read ↗

Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.Semantic proximity Read ↗

Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence during Roll-Out of Type-2 Novel Oral Polio VaccineSemantic proximity Read ↗

Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.Semantic proximity Read ↗

Evolution of the Sabin Vaccine into Pathogenic Derivatives without Appreciable Changes in Antigenic Properties: Need for Improvement of Current Poliovirus SurveillanceSemantic proximity Read ↗

First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adultsSemantic proximity Read ↗

Vaccine-derived polioviruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.